摘要
Background: Cardiovascular magnetic resonance (CMR) is the gold standard for non-invasive cardiovascular diagnosis. Conventional gadolinium-based contrast agents (GBCAs) carry potential gadolinium deposition risks, creating an unmet need for low-dose, high-relaxivity and high-safety next-generation agents. This study evaluated the preclinical efficacy, pharmacokinetics and safety of the novel ionic macrocyclic gadolinium contrast agent MS001-15. Methods: 1, In vitro efficacy: At 7.0T MRI, T1 relaxivity (r 1 ) of MS001-15, gadobutrol and Gadoquatrane was determined in human plasma and pure water. 2, In vivo efficacy: Balb/c mice received tail vein injection: gadobutrol at 0.1 mmol Gd/kg, while MS001-15 and Gadoquatrane at 0.04 mmol Gd/kg. Cerebrovascular MRI was performed at 0.5, 5, 15 and 30 min post-administration to assess signal enhancement. 3, Pharmacokinetics and excretion: SD rats were intravenously given 0.1 mmol Gd/kg of tested agents. Blood gadolinium concentration and 24-hour excretion rate were measured to calculate key pharmacokinetic parameters.4,Stability evaluation: A 7.0T relaxometry method was used to detect 48-hour transmetallation rate, so as to assess the risk of gadolinium dissociation. Results: 1,Superior in vitro relaxivity: At 7.0T, the plasma r 1 of MS001-15 was 8.67±0.10 mM − 1 ·s − 1 , and water r 1 was 11.94±0.11 mM − 1 ·s − 1 , significantly higher than the two controls (Table 1).2,Excellent low-dose imaging performance: At 0.04 mmol/kg, MS001-15 achieved a peak signal of 9.73±0.37, outperforming equal-dose Gadoquatrane and standard-dose gadobutrol with longer signal duration (Table 2).3,Favorable pharmacokinetics and excretion: MS001-15 presented higher in vivo exposure with an elimination half-life of only 3.42±0.16 h, reduced by over 53% versus controls. Its 24-hour total gadolinium excretion reached 57.81%, much higher than gadobutrol (40.28%) and Gadoquatrane (13.92%), with lower in vivo accumulation risk (Table 3).4,Reliable chemical stability: In the 48-hour transmetallation assay, MS001-15 exhibited favorable stability with an R 1 p(t)/R 1 p(0) ratio of 0.96 at 24 h and 0.95 at 48 h. It was significantly more stable than the linear agent Magnevist (0.86 at 24 h, 0.61 at 48 h) and comparable to macrocyclic controls gadobutrol and Gadoquatrane (~1.00 at all time points), indicating minimal risk of gadolinium dissociation. Conclusion: The novel ionic macrocyclic agent MS001-15 exhibits superior relaxivity and excellent imaging quality at a low dose of 0.04 mmol/kg, along with optimized pharmacokinetic profiles, rapid clearance and robust chemical stability. As a promising next-generation GBCA with low gadolinium deposition risk, MS001-15 provides a safer precise diagnostic option for cardiovascular patients requiring long-term CMR follow-up.